查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1825841

2025年全球癌症伴随诊断市场报告

Oncology Companion Diagnostics Global Market Report 2025
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10个工作天内

价格
简介目录

预计未来几年癌症伴随诊断市场将快速成长，到2029年将达到59.6亿美元，复合年增长率为12.0%。预测期内成长的主要驱动因素包括：个人化医疗的重要性日益提升、诊断检测的应用日益广泛、对个人化癌症治疗的日益关注、医疗保健支出的不断增长以及癌症发病率和认知度的不断提高。预测期内的主要趋势包括诊断技术的进步、新一代定序 (NGS)、人工智慧 (AI) 的整合、液态切片技术、照护现场伴随诊断设备的开发以及创新检测技术。

未来五年12.0%的预测成长率，较我们先前对该市场的预测略有下降0.6%。这一下降主要源自于美国与其他国家之间关税的影响。关税上涨可能会增加基于下一代定序 (NGS) 的生物标记检测套组（德国）和数位病理学人工智慧软体（加拿大）的成本，从而阻碍标靶治疗的发展，加剧患者的检测成本，并延迟获得标靶治疗的机会。由于互惠关税以及贸易紧张局势和限制措施的加剧对全球经济和贸易的负面影响，其影响也将更加广泛。

癌症盛行率的上升预计将在未来推动癌症伴随诊断市场的成长。癌症是一组复杂的疾病，其特征是细胞异常增殖且不受控制地扩散。癌症患者数量的增加归因于生活方式的改变、环境影响、肥胖症流行、吸烟和遗传易感性等因素。癌症伴随诊断在精准医疗中发挥关键作用，它透过实现个人化治疗方法选择、提高治疗效果、减少副作用、促进临床试验参与和加强治疗监测来改变癌症治疗。例如，美国国家癌症研究所于2024年5月报告称，2022年每年将新增约2,000万例癌症病例，并有970万人死于癌症。 2040年，预计每年新增癌症病例数将增加至2,990万例，癌症相关死亡人数将增加至1,530万例。因此，癌症盛行率的上升正在推动癌症伴随诊断市场的成长。

目录

第一章执行摘要

第二章 市场特征

第三章 市场趋势与策略

第四章 市场：宏观经济情景，包括利率、通膨、地缘政治、贸易战和关税，以及新冠疫情和復苏对市场的影响

第五章 全球成长分析与策略分析框架

  • 全球癌症伴随诊断：PESTEL 分析（政治、社会、技术、环境、法律因素、驱动因素和限制因素）
  • 最终用途产业分析
  • 全球癌症伴随诊断市场：成长率分析
  • 全球癌症伴随诊断市场表现：规模与成长，2019-2024
  • 全球癌症伴随诊断市场预测：规模与成长，2024-2029 年，2034 年
  • 全球癌症伴随诊断：总目标市场（TAM）

第六章 市场细分

  • 全球癌症伴随诊断市场（依产品、绩效及预测），2019-2024 年、2024-2029 年、2034 年
  • 装置
  • 耗材
  • 软体
  • 全球癌症伴随诊断市场（按疾病类型、表现和预测），2019-2024 年、2024-2029 年、2034 年
  • 黑色素瘤
  • 乳癌
  • 大肠直肠癌
  • 白血病
  • 摄护腺癌
  • 其他的
  • 全球癌症伴随诊断市场（按技术、绩效和预测），2019-2024 年、2024-2029 年、2034 年
  • 免疫组织化学（IHC）
  • 原位杂合反应（ISH）或萤光原位杂合反应（FISH）
  • 聚合酵素链锁反应（PCR）
  • 下一代定序（NGS）
  • 其他的
  • 全球癌症伴随诊断市场（按最终用户、绩效和预测），2019-2024 年、2024-2029 年、2034 年
  • 医院
  • 病理或诊断实验室
  • 学术医疗中心
  • 其他的
  • 全球癌症伴随诊断市场：设备细分、类型、性能和预测，2019-2024 年、2024-2029 年、2034 年
  • 聚合酵素链锁反应（PCR）设备
  • 下一代定序（NGS）系统
  • 免疫组织化学（IHC）设备
  • 萤光原位杂合反应（FISH）设备
  • 微阵列平台
  • 全球癌症伴随诊断市场：耗材细分、类型、绩效及预测，2019-2024、2024-2029、2034
  • 试剂及套件（DNA或RNA萃取套件、PCR试剂）
  • 切片穿刺针
  • 滑动和晶片测试
  • 控制和校准样品
  • 全球癌症伴随诊断市场：软体细分、类型、效能和预测（2019-2024 年、2024-2029 年、2034 年）
  • 数据分析软体
  • 生物资讯软体（用于基因表现分析）
  • 伴随诊断决策支援软体
  • 临床工作流程管理软体

第七章 区域和国家分析

  • 全球癌症伴随诊断市场各地区、绩效及预测（2019-2024、2024-2029、2034）
  • 全球癌症伴随诊断市场（按国家/地区划分）、绩效及预测（2019-2024 年、2024-2029 年、2034 年）

第八章 亚太市场

第九章：中国市场

第十章 印度市场

第十一章 日本市场

第十二章：澳洲市场

第十三章 印尼市场

第十四章 韩国市场

第十五章 西欧市场

第十六章英国市场

第十七章：德国市场

第18章：法国市场

第十九章：义大利市场

第20章：西班牙市场

第21章 东欧市场

第22章俄罗斯市场

第23章 北美市场

第24章美国市场

第25章：加拿大市场

第26章 南美洲市场

第27章：巴西市场

第28章 中东市场

第29章：非洲市场

第30章：竞争格局与公司概况

  • 癌症伴随诊断市场：竞争格局
  • 癌症伴随诊断市场：公司简介
    • F. Hoffmann-La Roche AG
    • Bayer Diagnostic
    • Thermo Fisher Scientific Inc.
    • Abbott Laboratories
    • Danaher Corporation

第31章：其他领先和创新企业

  • Laboratory Corporation of America Holdings（LabCorp）
  • Quest Diagnostics Incorporated
  • Eurofins Scientific SE
  • Agilent Technologies Inc.
  • Illumina Inc.
  • PerkinElmer Inc.
  • bioMerieux SA
  • Sysmex Corporation
  • Bio-Rad Laboratories Inc.
  • QIAGEN NV
  • Exact Sciences Corporation
  • BGI Genomics Co. Ltd.
  • Natera Inc.
  • Myriad Genetics Inc.
  • ARUP Laboratories

第 32 章全球市场竞争基准化分析与仪表板

第33章 重大併购

第34章近期市场趋势

第35章：市场潜力大的国家与策略

  • 2029年癌症伴随诊断市场：提供新机会的国家
  • 2029年癌症伴随诊断市场：细分市场带来新机会
  • 2029年癌症伴随诊断市场：成长策略
    • 基于市场趋势的策略
    • 竞争对手策略

第36章 附录

简介目录
Product Code: r30813u

Oncology companion diagnostics are medical tests designed to identify specific biomarkers, indicating which patients are most likely to respond favorably to a particular cancer treatment. These diagnostics play a crucial role in the development and application of targeted therapies, ensuring that treatments are customized to match the unique characteristics of a patient's tumor. By providing insights into the molecular and genetic profile of cancer, companion diagnostics enable more personalized and efficient treatment strategies, leading to improved outcomes and reduced adverse effects.

The primary products within the oncology companion diagnostics market include instruments, consumables, and software. Instruments encompass a diverse array of tools and devices utilized for various purposes across different fields. These diagnostics cater to a range of disease types such as melanoma, breast cancer, colorectal cancer, leukemia, prostate cancer, among others. They leverage various technologies including immunohistochemistry (IHC), in situ hybridization (ISH) or fluorescence in situ hybridization (FISH), polymerase chain reaction (PCR), next-generation sequencing (NGS), and others. End users of oncology companion diagnostics include hospitals, pathology or diagnostic laboratories, academic medical centers, and others.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The oncology companion diagnostics market research report is one of a series of new reports from The Business Research Company that provides oncology companion diagnostics market statistics, including oncology companion diagnostics industry global market size, regional shares, competitors with an oncology companion diagnostics market share, detailed oncology companion diagnostics market segments, market trends, and opportunities, and any further data you may need to thrive in the oncology companion diagnostics industry. This oncology companion diagnostics research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The oncology companion diagnostics market size has grown rapidly in recent years. It will grow from $3.35 billion in 2024 to $3.79 billion in 2025 at a compound annual growth rate (CAGR) of 13.2%. The growth in the historic period can be attributed to increasing cases of adverse drug reactions, increasing demand for comprehensive genomic testing, the increasing global incidence of cancer, the growing need for targeted therapy, and the growing number of clinical trials.

The oncology companion diagnostics market size is expected to see rapid growth in the next few years. It will grow to $5.96 billion in 2029 at a compound annual growth rate (CAGR) of 12.0%. The growth in the forecast period can be attributed to the rising importance of personalized medicine, increasing diagnostic tests, increasing focus on personalized cancer therapy, increasing healthcare expenditure, and increasing cancer incidence and awareness. Major trends in the forecast period include advancements in diagnostic technologies, next-generation sequencing (NGS), integration of artificial intelligence (AI), liquid biopsy technologies, the development of point-of-care companion diagnostic devices, and innovative testing technologies.

The forecast of 12.0% growth over the next five years reflects a modest reduction of 0.6% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff escalations are likely to impede precision medicine by driving up the cost of Next-Generation Sequencing(NGS)-based biomarker test kits (Germany) and digital pathology AI software (Canada), exacerbating patient testing costs and delaying targeted therapy access. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing prevalence of cancer is expected to drive the growth of the oncology companion diagnostics market in the future. Cancer is a complex group of diseases characterized by abnormal cell growth that spreads uncontrollably. The rise in cancer cases can be attributed to factors such as lifestyle changes, environmental influences, the obesity epidemic, tobacco use, and genetic predispositions. Oncology companion diagnostics play a critical role in precision medicine, transforming cancer care by enabling personalized treatment selection, improving treatment effectiveness, reducing side effects, facilitating clinical trial participation, and enhancing treatment monitoring. For example, the National Cancer Institute, a US-based government agency, reported in May 2024 that approximately 20 million new cancer cases and 9.7 million cancer-related deaths occurred annually in 2022. By 2040, predictions suggest that the number of new cancer cases will rise to 29.9 million, with 15.3 million cancer-related deaths annually. As a result, the increasing cancer incidence is driving the growth of the oncology companion diagnostics market.

Leading companies in the oncology companion diagnostics market are concentrating their efforts on developing innovative products, particularly in vitro diagnostic tests, to maintain their competitive edge. In vitro diagnostic tests, conducted on samples obtained from patients outside of the body in controlled laboratory environments, provide critical insights into tumor biology and guide treatment decision-making. For example, Illumina Inc., a prominent biotechnology company, introduced a pan-cancer companion diagnostic (CDx) indication for its TruSight Oncology (TSO) Comprehensive (EU) test in May 2022. This diagnostic assay offers a comprehensive tumor profile by evaluating multiple tumor genes and biomarkers, empowering healthcare providers to tailor targeted therapy for patients with various solid malignant neoplasms. By assessing essential parameters such as tumor mutational burden (TMB) and microsatellite instability (MSI) status, this test enhances treatment precision and effectiveness.

In January 2024, Agilent Technologies Inc., a US-based diagnostics company, entered into a partnership with Incyte Corporation for an undisclosed amount. This collaboration aims to strengthen Agilent's companion diagnostics portfolio and support Incyte's hematology and oncology treatments through advanced, precision diagnostics. Incyte Corporation, a US-based pharmaceutical company, specializes in the development and commercialization of oncology medications.

Major companies operating in the oncology companion diagnostics market are F. Hoffmann-La Roche AG, Bayer Diagnostic, Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Laboratory Corporation of America Holdings (LabCorp), Quest Diagnostics Incorporated, Eurofins Scientific SE, Agilent Technologies Inc., Illumina Inc., PerkinElmer Inc., bioMerieux SA, Sysmex Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Exact Sciences Corporation, BGI Genomics Co. Ltd., Natera Inc., Myriad Genetics Inc., ARUP Laboratories, NeoGenomics Laboratories Inc., Guardant Health, Ambry Genetics Corporation, Biocartis SA, CENTOGENE N.V., Invivoscribe Inc., Pillar Biosciences Inc.

North America was the largest region in the oncology companion diagnostic market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oncology companion diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the oncology companion diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The oncology companion diagnostics market consists of revenues earned by entities by providing services such as biomarker testing, patient stratification, monitoring treatment response, predicting drug resistance, clinical trial enrollment, comprehensive genomic testing, therapy resistance testing, hereditary cancer testing, and risk assessment. The market value includes the value of related goods sold by the service provider or included within the service offering. The oncology companion diagnostics market also includes sales of polymerase chain reaction instruments, immunohistochemistry (IHC) staining kits, companion diagnostic test kits, liquid biopsy platforms, gene expression profiling kits, mass spectrometry systems, flow cytometry analyzers, tissue microarray instruments, and electrochemical biosensors. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Oncology Companion Diagnostics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on oncology companion diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for oncology companion diagnostics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The oncology companion diagnostics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Product: Instrument; Consumables; Software
  • 2) By Disease Type: Melanoma; Breast Cancer; Colorectal Cancer; Leukemia; Prostate Cancer; Other Disease Types
  • 3) By Technology: Immunohistochemistry (IHC); In Situ Hybridization (ISH) Or Fluorescence In Situ Hybridization (FISH); Polymerase Chain Reaction (PCR); Next-Generation Sequencing (NGS); Other Technologies
  • 4) By End User: Hospital; Pathology Or Diagnostic Laboratory; Academic Medical Center; Other End-Users
  • Subsegments:
  • 1) By Instrument: Polymerase Chain Reaction (Pcr) Instruments; Next-Generation Sequencing (Ngs) Systems; Immunohistochemistry (Ihc) Instruments; Fluorescence In Situ Hybridization (Fish) Instruments; Microarray Platforms
  • 2) By Consumables: Reagents And Kits (Dna Or Rna Extraction Kits, Pcr Reagents); Biopsy Needles; Testing Slides And Chips; Control And Calibration Samples
  • 3) By Software: Data Analysis Software; Bioinformatics Software ( For Gene Expression Analysis); Companion Diagnostic Decision Support Software; Clinical Workflow Management Software
  • Companies Mentioned: F. Hoffmann-La Roche AG; Bayer Diagnostic; Thermo Fisher Scientific Inc.; Abbott Laboratories; Danaher Corporation; Laboratory Corporation of America Holdings (LabCorp); Quest Diagnostics Incorporated; Eurofins Scientific SE; Agilent Technologies Inc.; Illumina Inc.; PerkinElmer Inc.; bioMerieux SA; Sysmex Corporation; Bio-Rad Laboratories Inc.; QIAGEN N.V.; Exact Sciences Corporation; BGI Genomics Co. Ltd.; Natera Inc.; Myriad Genetics Inc.; ARUP Laboratories; NeoGenomics Laboratories Inc.; Guardant Health; Ambry Genetics Corporation; Biocartis SA; CENTOGENE N.V.; Invivoscribe Inc.; Pillar Biosciences Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Oncology Companion Diagnostics Market Characteristics

3. Oncology Companion Diagnostics Market Trends And Strategies

4. Oncology Companion Diagnostics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

  • 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Oncology Companion Diagnostics Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Oncology Companion Diagnostics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Oncology Companion Diagnostics Market Growth Rate Analysis
  • 5.4. Global Oncology Companion Diagnostics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Oncology Companion Diagnostics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Oncology Companion Diagnostics Total Addressable Market (TAM)

6. Oncology Companion Diagnostics Market Segmentation

  • 6.1. Global Oncology Companion Diagnostics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Instrument
  • Consumables
  • Software
  • 6.2. Global Oncology Companion Diagnostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Melanoma
  • Breast Cancer
  • Colorectal Cancer
  • Leukemia
  • Prostate Cancer
  • Other Disease Types
  • 6.3. Global Oncology Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Immunohistochemistry (IHC)
  • In Situ Hybridization (ISH) Or Fluorescence In Situ Hybridization (FISH)
  • Polymerase Chain Reaction (PCR)
  • Next-Generation Sequencing (NGS)
  • Other Technologies
  • 6.4. Global Oncology Companion Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospital
  • Pathology Or Diagnostic Laboratory
  • Academic Medical Center
  • Other End-Users
  • 6.5. Global Oncology Companion Diagnostics Market, Sub-Segmentation Of Instrument, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Polymerase Chain Reaction (PCR) Instruments
  • Next-Generation Sequencing (NGS) Systems
  • Immunohistochemistry (IHC) Instruments
  • Fluorescence In Situ Hybridization (FISH) Instruments
  • Microarray Platforms
  • 6.6. Global Oncology Companion Diagnostics Market, Sub-Segmentation Of Consumables, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Reagents And Kits (DNA Or RNA Extraction Kits, PCR Reagents)
  • Biopsy Needles
  • Testing Slides And Chips
  • Control And Calibration Samples
  • 6.7. Global Oncology Companion Diagnostics Market, Sub-Segmentation Of Software, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Data Analysis Software
  • Bioinformatics Software (For Gene Expression Analysis)
  • Companion Diagnostic Decision Support Software
  • Clinical Workflow Management Software

7. Oncology Companion Diagnostics Market Regional And Country Analysis

  • 7.1. Global Oncology Companion Diagnostics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Oncology Companion Diagnostics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Oncology Companion Diagnostics Market

  • 8.1. Asia-Pacific Oncology Companion Diagnostics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Oncology Companion Diagnostics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Oncology Companion Diagnostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Oncology Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Oncology Companion Diagnostics Market

  • 9.1. China Oncology Companion Diagnostics Market Overview
  • 9.2. China Oncology Companion Diagnostics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Oncology Companion Diagnostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Oncology Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Oncology Companion Diagnostics Market

  • 10.1. India Oncology Companion Diagnostics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Oncology Companion Diagnostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Oncology Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Oncology Companion Diagnostics Market

  • 11.1. Japan Oncology Companion Diagnostics Market Overview
  • 11.2. Japan Oncology Companion Diagnostics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Oncology Companion Diagnostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Oncology Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Oncology Companion Diagnostics Market

  • 12.1. Australia Oncology Companion Diagnostics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Oncology Companion Diagnostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Oncology Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Oncology Companion Diagnostics Market

  • 13.1. Indonesia Oncology Companion Diagnostics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Oncology Companion Diagnostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Oncology Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Oncology Companion Diagnostics Market

  • 14.1. South Korea Oncology Companion Diagnostics Market Overview
  • 14.2. South Korea Oncology Companion Diagnostics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Oncology Companion Diagnostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Oncology Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Oncology Companion Diagnostics Market

  • 15.1. Western Europe Oncology Companion Diagnostics Market Overview
  • 15.2. Western Europe Oncology Companion Diagnostics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Oncology Companion Diagnostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Oncology Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Oncology Companion Diagnostics Market

  • 16.1. UK Oncology Companion Diagnostics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Oncology Companion Diagnostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Oncology Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Oncology Companion Diagnostics Market

  • 17.1. Germany Oncology Companion Diagnostics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Oncology Companion Diagnostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Oncology Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Oncology Companion Diagnostics Market

  • 18.1. France Oncology Companion Diagnostics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Oncology Companion Diagnostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Oncology Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Oncology Companion Diagnostics Market

  • 19.1. Italy Oncology Companion Diagnostics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Oncology Companion Diagnostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Oncology Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Oncology Companion Diagnostics Market

  • 20.1. Spain Oncology Companion Diagnostics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Oncology Companion Diagnostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Oncology Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Oncology Companion Diagnostics Market

  • 21.1. Eastern Europe Oncology Companion Diagnostics Market Overview
  • 21.2. Eastern Europe Oncology Companion Diagnostics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Oncology Companion Diagnostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Oncology Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Oncology Companion Diagnostics Market

  • 22.1. Russia Oncology Companion Diagnostics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Oncology Companion Diagnostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Oncology Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Oncology Companion Diagnostics Market

  • 23.1. North America Oncology Companion Diagnostics Market Overview
  • 23.2. North America Oncology Companion Diagnostics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Oncology Companion Diagnostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Oncology Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Oncology Companion Diagnostics Market

  • 24.1. USA Oncology Companion Diagnostics Market Overview
  • 24.2. USA Oncology Companion Diagnostics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Oncology Companion Diagnostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Oncology Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Oncology Companion Diagnostics Market

  • 25.1. Canada Oncology Companion Diagnostics Market Overview
  • 25.2. Canada Oncology Companion Diagnostics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Oncology Companion Diagnostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Oncology Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Oncology Companion Diagnostics Market

  • 26.1. South America Oncology Companion Diagnostics Market Overview
  • 26.2. South America Oncology Companion Diagnostics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Oncology Companion Diagnostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Oncology Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Oncology Companion Diagnostics Market

  • 27.1. Brazil Oncology Companion Diagnostics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Oncology Companion Diagnostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Oncology Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Oncology Companion Diagnostics Market

  • 28.1. Middle East Oncology Companion Diagnostics Market Overview
  • 28.2. Middle East Oncology Companion Diagnostics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Oncology Companion Diagnostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Oncology Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Oncology Companion Diagnostics Market

  • 29.1. Africa Oncology Companion Diagnostics Market Overview
  • 29.2. Africa Oncology Companion Diagnostics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Oncology Companion Diagnostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Oncology Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Oncology Companion Diagnostics Market Competitive Landscape And Company Profiles

  • 30.1. Oncology Companion Diagnostics Market Competitive Landscape
  • 30.2. Oncology Companion Diagnostics Market Company Profiles
    • 30.2.1. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Bayer Diagnostic Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Danaher Corporation Overview, Products and Services, Strategy and Financial Analysis

31. Oncology Companion Diagnostics Market Other Major And Innovative Companies

  • 31.1. Laboratory Corporation of America Holdings (LabCorp)
  • 31.2. Quest Diagnostics Incorporated
  • 31.3. Eurofins Scientific SE
  • 31.4. Agilent Technologies Inc.
  • 31.5. Illumina Inc.
  • 31.6. PerkinElmer Inc.
  • 31.7. bioMerieux SA
  • 31.8. Sysmex Corporation
  • 31.9. Bio-Rad Laboratories Inc.
  • 31.10. QIAGEN N.V.
  • 31.11. Exact Sciences Corporation
  • 31.12. BGI Genomics Co. Ltd.
  • 31.13. Natera Inc.
  • 31.14. Myriad Genetics Inc.
  • 31.15. ARUP Laboratories

32. Global Oncology Companion Diagnostics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Oncology Companion Diagnostics Market

34. Recent Developments In The Oncology Companion Diagnostics Market

35. Oncology Companion Diagnostics Market High Potential Countries, Segments and Strategies

  • 35.1 Oncology Companion Diagnostics Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Oncology Companion Diagnostics Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Oncology Companion Diagnostics Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer